Nonprofit Group I-MAK Files IPR Petitions Seeking to Invalidate Hepatitis C Drug Patent

Media Article 26 Oct 2017

In an effort to lay the groundwork for generic entry and reduced drug prices, the non-profit group Initiative for Medicines, Access and Knowledge, Inc. (I-MAK), with the support of the Laura and John Arnold foundation, has petitioned the PTAB seeking Inter Partes Review of Gilead’s U.S. Patent Nos. 7,429,572 & 7,964,580, which purport to encompass sofosbuvir, one of the active components of anti-Hepatitis C drugs Sovaldi®, Harvoni®, and Epclusa®.  I-MAK v. Gilead, IPR2018-00103, IPR2018-00119 & IPR2018-00120.  The challenged patents are said to cover methods and compositions for treating Hepatitis C using nucleoside analogs, including sofosbuvir.

Partner with us now to build
a more just and equitable
medicine system for all.